Author

R. Sritharan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:biophysical modeling· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. B. Francisco· 1 shared A. P. Massa· 1 shared C. G. Danko· 1 shared F. D. Smith· 1 shared J. D. Scott· 1 shared M. Kanke· 1 shared P. Sethupathy· 1 shared R. K. Ma· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. B. Francisco

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal molecular mechanisms of oncogenesis and intrinsic drug resistance

T. A. Dinh, R. Sritharan, F. D. Smith, A. B. Francisco, R. K. Ma, R. P. Bunaciu, M. Kanke, C. G. Danko, A. P. Massa, J. D. Scott, P. Sethupathy

This study identifies aberrant enhancer activity in fibrolamellar carcinoma, revealing molecular mechanisms of oncogenesis and drug resistance, and suggests new therapeutic targets.

bioRxiv · Jan 18, 2020 · PreprintCancer Biology